The significance of MRD-based strategy by dynamic assessment to guide treatment decisions in B-ALL - the enlightenment provided by demonstrating survival differences in the retrospective study

Yongyu Chen ¹, Rongrong Liu ¹, Jing Li ¹

⁰Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.

Hematology (amsterdam, Netherlands) +

|

October 17, 2024

View abstract on PubMed

Summary

Maintaining negative measurable residual disease (MRD) status after chemotherapy significantly improves long-term survival for B-cell acute lymphoblastic leukemia (B-ALL) patients. Dynamic MRD monitoring aids treatment selection and enhances patient prognosis.

Area Of Science

Hematology
Oncology
Clinical Research

Background

B-cell acute lymphoblastic leukemia (B-ALL) is a significant hematologic malignancy.
Long-term survival and treatment strategies for B-ALL require continuous refinement.
Understanding prognostic factors is crucial for improving patient outcomes.

Purpose Of The Study

To evaluate the impact of clinical factors on B-ALL patient survival.
To determine the significance of dynamic measurable residual disease (MRD) assessment in B-ALL prognosis.
To guide treatment selection and improve survival rates in B-ALL patients.

Main Methods

Clinical data from 65 B-ALL patients were analyzed.
Overall survival (OS) and progression-free survival (PFS) were calculated.
Survival analysis was performed using dynamic MRD assessment post-induction chemotherapy.

Main Results

Patients maintaining MRD-negative status after induction chemotherapy showed significantly better PFS (P=0.0002).
High-risk B-ALL patients with sustained MRD negativity experienced longer PFS (P=0.0016).
Dynamic MRD assessment demonstrated a strong correlation with improved survival outcomes.

Conclusions

Dynamic MRD assessment is clinically valuable for B-ALL management.
Sustained MRD negativity is associated with improved prognosis and survival.
MRD monitoring post-chemotherapy can guide treatment decisions and inform future strategies.

Keywords:

Acute lymphoblastic leukemia clinical hematology hematopoietic cell transplantation measurable residual disease therapy